tiprankstipranks
Ascentage Pharma Group International (HK:6855)
:6855
Hong Kong Market
6855
Ascentage Pharma Group International
RESEARCH TOOLSreports

Ascentage Pharma Group International (6855) Stock Forecast & Price Target

Compare
4 Followers
See the Price Targets and Ratings of:

6855 Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Ascentage
Pharma Group International
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6855 Stock 12 Month Forecast

There Are No Analyst Ratings for HK:6855 In The Last 3 Months.
Highest Price Target―Average Price Target―Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

6855 Financial Forecast

6855 Earnings Forecast

Next quarter’s earnings estimate for 6855 is -HK$0.51 with a range of -HK$0.57 to -HK$0.45. The previous quarter’s EPS was -HK$0.55. 6855 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 6855 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6855 is -HK$0.51 with a range of -HK$0.57 to -HK$0.45. The previous quarter’s EPS was -HK$0.55. 6855 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 6855 has Performed in-line its overall industry.

6855 Sales Forecast

Next quarter’s sales forecast for 6855 is HK$391.89M with a range of HK$332.15M to HK$484.02M. The previous quarter’s sales results were HK$372.68M. 6855 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 6855 has Performed in-line its overall industry.
Next quarter’s sales forecast for 6855 is HK$391.89M with a range of HK$332.15M to HK$484.02M. The previous quarter’s sales results were HK$372.68M. 6855 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 6855 has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CICC Analyst forecast on HK:6855
Unknown Analyst
CICC
Not Ranked
CICC
HK$89
Buy
74.85%
Upside
Reiterated
12/16/25
Ascentage Pharma Group International (6855) Receives a Buy from CICC
Guotai Haitong Analyst forecast on HK:6855
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$90.7
Buy
78.19%
Upside
Reiterated
08/22/25
SPDB Analyst forecast on HK:6855
Unknown Analyst
SPDB
Not Ranked
SPDB
HK$105
Buy
106.29%
Upside
Reiterated
08/22/25
Citi Analyst forecast on HK:6855
Unknown Analyst
Citi
Not Ranked
Citi
HK$114
Buy
123.97%
Upside
Reiterated
08/21/25
J.P. Morgan Analyst forecast on HK:6855
Yang Huang
J.P. Morgan
J.P. Morgan
HK$93
Buy
82.71%
Upside
Reiterated
08/07/25
J.P. Morgan Sticks to Its Buy Rating for Ascentage Pharma Group International (6855)
Guoyuan Securities (HK) Analyst forecast on HK:6855
Unknown Analyst
Guoyuan Securities (HK)
Not Ranked
Guoyuan Securities (HK)
HK$87.81
Buy
72.51%
Upside
Reiterated
06/20/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CICC Analyst forecast on HK:6855
Unknown Analyst
CICC
Not Ranked
CICC
HK$89
Buy
74.85%
Upside
Reiterated
12/16/25
Ascentage Pharma Group International (6855) Receives a Buy from CICC
Guotai Haitong Analyst forecast on HK:6855
Unknown Analyst
Guotai Haitong
Not Ranked
Guotai Haitong
HK$90.7
Buy
78.19%
Upside
Reiterated
08/22/25
SPDB Analyst forecast on HK:6855
Unknown Analyst
SPDB
Not Ranked
SPDB
HK$105
Buy
106.29%
Upside
Reiterated
08/22/25
Citi Analyst forecast on HK:6855
Unknown Analyst
Citi
Not Ranked
Citi
HK$114
Buy
123.97%
Upside
Reiterated
08/21/25
J.P. Morgan Analyst forecast on HK:6855
Yang Huang
J.P. Morgan
J.P. Morgan
HK$93
Buy
82.71%
Upside
Reiterated
08/07/25
J.P. Morgan Sticks to Its Buy Rating for Ascentage Pharma Group International (6855)
Guoyuan Securities (HK) Analyst forecast on HK:6855
Unknown Analyst
Guoyuan Securities (HK)
Not Ranked
Guoyuan Securities (HK)
HK$87.81
Buy
72.51%
Upside
Reiterated
06/20/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascentage Pharma Group International

3 Months
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+27.60%
reiterated a xxx
 rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +27.60% per trade.
1 Year
Google Health Care HKTipRanks - Google
Success Rate
1/1 ratings generated profit
100%
Average Return
+31.50%
reiterated a sell rating 2 months ago
Copying Google Health Care HK's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.50% per trade.
2 Years
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+31.50%
reiterated a xxx
 rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +31.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6855 Analyst Recommendation Trends

Rating
Sep 25
Oct 25
Dec 25
Jan 26
Feb 26
Strong Buy
0
0
1
1
1
Buy
4
4
0
0
0
Hold
7
19
17
21
16
Sell
1
4
4
5
6
Strong Sell
0
0
0
0
0
total
12
27
22
27
23
In the current month, 6855 has received 1 Buy Ratings, 16 Hold Ratings, and 6 Sell Ratings. 6855 average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.

6855 Stock Forecast FAQ

What is HK:6855’s average 12-month price target, according to analysts?
Currently, no data Available
What is HK:6855’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for HK:6855, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Ascentage Pharma Group International a Buy, Sell or Hold?
      Currently, no data Available
      What is Ascentage Pharma Group International’s share price target?
      Currently, no data Available
      What do analysts say about Ascentage Pharma Group International?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Ascentage Pharma Group International?
      To buy shares of HK:6855, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.